Pharmaceutical sleep aids. In 2006, consumers spent $3.6 billion on prescription sleep medications, up 29% from 2005, according to health care and pharmaceutical consulting company IMS Health. It reports that more than 48 million sleep-aid prescriptions were written last year

VEC-162 is designed to treat patients with circadian rhythm sleep disorders, or CRSD. These are people such as shift workers whose internal sleep/wake cycle does not match their desired sleep time.

The American Psychological Association (APA) recently published a study on the new sleep aid ramelteon ( brand name Rozerem). The focus of the study was abuse and tolerance. The gist of it is that ramelteon, marketed by Takeda as Rozerem, has a totally different method of action from all other sleeping […]